Nivolumab–relatlimab

Status:

Red

Decision Date:

February 2024

Comments

RED: NICE TA950 - for untreated unresectable or metastatic melanoma in people 12 years and over. NHSE commissioned. (Decision date - February/March 2024)

Red Drug Classifications

• 8. NHS England commissioned – to be used in line with NHSE commissioning intentions

search again